Drug-induced liver injury in older people.

Adult Age Factors Aged Aged, 80 and over Anti-Infective Agents / adverse effects Cardiovascular Agents / adverse effects Chemical and Drug Induced Liver Injury / epidemiology Cholestasis / chemically induced Comorbidity Dietary Supplements / adverse effects Female Humans Incidence Male Middle Aged Palliative Care Pharmacokinetics Phenotype Plants, Medicinal / adverse effects Polypharmacy Risk Factors

Journal

The lancet. Gastroenterology & hepatology
ISSN: 2468-1253
Titre abrégé: Lancet Gastroenterol Hepatol
Pays: Netherlands
ID NLM: 101690683

Informations de publication

Date de publication:
09 2020
Historique:
received: 21 11 2019
revised: 08 01 2020
accepted: 08 01 2020
entrez: 21 8 2020
pubmed: 21 8 2020
medline: 15 9 2020
Statut: ppublish

Résumé

Drug-induced liver injury (DILI) is a rare, unpredictable, and potentially serious adverse reaction. It is induced by many drugs, herbs, and dietary supplements and represents a diagnostic challenge to clinicians. Older people (aged 65 years and older) are often polymedicated, and their declining physiological function affects drug pharmacokinetics. There is no consistent evidence that age is a general risk factor for DILI; however, age might be a risk factor with specific medications, with antimicrobials and cardiovascular drugs being the most likely medications to cause DILI in older people. Ageing influences DILI phenotypes, making cholestatic damage and chronic DILI more likely. In older people with DILI, comorbidities act as confounding causes and account for higher mortality unrelated to the liver. There are no specific therapies for DILI and supportive measures are still the mainstay of management. This Review highlights current advances and gaps in DILI epidemiology, mechanisms, and diagnosis that are pertinent to older individuals.

Identifiants

DOI: 10.1016/S2468-1253(20)30006-6 PMID: 32818465
pubmed: 32818465
pii: S2468-1253(20)30006-6
doi: 10.1016/S2468-1253(20)30006-6
pii:
doi:

Substances chimiques

Anti-Infective Agents 0
Cardiovascular Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

862-874

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Auteurs

M Isabel Lucena (MI)

Servicio de Farmacología Clínica, Instituto de Investigación Biomédica de Málaga-IBIMA, Hospital Universitario Virgen de la Victoria, Universidad de Málaga, Malaga, Spain; Platform for Clinical Research and Clinical Trials IBIMA, Spanish Clinical Research Network (SCReN), Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain. Electronic address: lucena@uma.es.

Judith Sanabria (J)

Servicio de Farmacología Clínica, Instituto de Investigación Biomédica de Málaga-IBIMA, Hospital Universitario Virgen de la Victoria, Universidad de Málaga, Malaga, Spain; Platform for Clinical Research and Clinical Trials IBIMA, Spanish Clinical Research Network (SCReN), Madrid, Spain.

Miren García-Cortes (M)

Servicio de Ap Digestivo, Instituto de Investigación Biomédica de Málaga-IBIMA, Hospital Universitario Virgen de la Victoria, Universidad de Málaga, Malaga, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain.

Camilla Stephens (C)

Servicio de Farmacología Clínica, Instituto de Investigación Biomédica de Málaga-IBIMA, Hospital Universitario Virgen de la Victoria, Universidad de Málaga, Malaga, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain.

Raúl J Andrade (RJ)

Servicio de Farmacología Clínica, Instituto de Investigación Biomédica de Málaga-IBIMA, Hospital Universitario Virgen de la Victoria, Universidad de Málaga, Malaga, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Drug-induced liver injury in older people.
questionsmedicales.fr › Environnement et santé publique › Santé publique › Facteurs épidémiologiques › Facteurs âges › Drug-induced liver injury in older people.
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Drug-induced liver injury in older people.
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Sujet âgé de 80 ans ou plus › Drug-induced liver injury in older people.
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Drug-induced liver injury in older people.
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Agents cardiovasculaires › Drug-induced liver injury in older people.
questionsmedicales.fr › Troubles dus à des produits chimiques › Intoxication › Lésions hépatiques dues aux substances › Drug-induced liver injury in older people.
questionsmedicales.fr › Maladies de l'appareil digestif › Maladie des voies biliaires › Maladies des canaux biliaires › Cholestase › Drug-induced liver injury in older people.
questionsmedicales.fr › Environnement et santé publique › Santé publique › Facteurs épidémiologiques › Comorbidité › Drug-induced liver injury in older people.
questionsmedicales.fr › Aliments et boissons › Aliments › Compléments alimentaires › Drug-induced liver injury in older people.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Drug-induced liver injury in older people.
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Registre civil › Morbidité › Incidence › Drug-induced liver injury in older people.
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Drug-induced liver injury in older people.
questionsmedicales.fr › Établissements, main d'oeuvre et services de soins de santé › Services de santé › Soins aux patients › Soins palliatifs › Drug-induced liver injury in older people.
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Pharmacocinétique › Drug-induced liver injury in older people.
questionsmedicales.fr › Phénomènes génétiques › Phénotype › Drug-induced liver injury in older people.
questionsmedicales.fr › Eucaryotes › Plantes › Plantes médicinales › Drug-induced liver injury in older people.
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Prestations des soins de santé › Attitude envers la santé › Mésusage des services de santé › Surmédicalisation › Traitement excessif › Polypharmacie › Drug-induced liver injury in older people.
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Probabilité › Risque › Facteurs de risque › Drug-induced liver injury in older people.